Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers
2023-000964-70Phase 3
- Sponsor
- Sanofi
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing PCV21 arm with 20vPCV comparator arm (2 arms). Primary endpoint: Serotype-specific IgG seroresponse rate after dose 3.
02
Drugs
SP0202Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2023-000964-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000964-70.